Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in Adult and Adolescent Participants With Severe Asthma (PASSAGE)
NCT05329194Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tezepelumab in asthma, sponsored by AstraZeneca. Primary endpoint: Annualized Asthma Exacerbation Rate at Week 52. Started Apr 2022; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05329194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329194.